. >> we'll have our new headquarters in the heart of the tenderloin at taylor and kushlg at the end of this summer 2014 we're really excited. >> a lot of the of the conditions in san francisco they have in the rest of the country so our goal to 257bd or expand out of the san francisco in los angeles and then after that who know. >> we'd never want to tell people want to do or eat only provide the skills and the tools in case that's something people are 2rrd in doing. >> you can't buy a box of psyche you have to put them in the right vein and direction with the right kids with a right place address time those kids don't have this you have to instill they can do it they're good enough now to finding out figure out and find the future for [ pledge of allegiance ] >> before we start the meeting, i just wanted to -- [ inaudible ] --

about patients what weren't able to li and work whose lives are transformed, it's really incredible kushlggo boys had to receive factory replacement because they're missing a factor that causes them to bleed. they would need factor replacement daily. then we had kind of the long acting factors, which are now being lunched by novo and by -- these basicry are two to three times a week, it's a little better, but -- not as combersome as before. potentially you could launch and have gene therapy for that factor, but you give the patient a gene yes. that's the whole point >> we're running out of time, but do you feel like we'll get a quantum -- it's a tv show. a quantum leap in all of the -- we've learned so much over the past 10, 15 years in basic science. some of it has made its way to the clinic or to the hospital bed, but i don't know. are you -- i'm frustrated by how much we know and how hard it is to design therapy mukts. there are so many things, testing and so many side effects and everything else. we know so much more yu i'm just looking for ration a.m. drug design lock and key type the